Salivary Gland Infection Global Market Report 2025

The salivary gland infection market size has grown strongly in recent years. It will grow from $4.12 billion in 2024 to $4.46 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to the rise in oral health issues, increased awareness of salivary disorders, a growing prevalence of bacterial and viral infections, expanding healthcare infrastructure, a rising geriatric population, and the increased adoption of minimally invasive treatments.

The salivary gland infection market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising awareness about oral health, the growing adoption of minimally invasive procedures, an increasing prevalence of chronic conditions, improvements in healthcare infrastructure, and expanded patient access to specialized care. Key trends include the adoption of minimally invasive procedures, advancements in sialendoscopy techniques, the development of advanced imaging technologies, biocompatible stent innovations, the rise of robotic-assisted surgeries, the use of targeted antimicrobial therapies, and the integration of AI-driven diagnostic tools.

The increasing prevalence of oral health issues is expected to drive the growth of the salivary gland infections market in the coming years. Oral health conditions, including tooth decay, gum infections, and other mouth-related problems, are on the rise due to poor oral hygiene, unhealthy eating habits, and limited access to dental care. These issues contribute to a higher risk of salivary gland infections by encouraging bacterial growth and causing blockages in the salivary ducts. For example, in May 2024, the National Health Service (NHS), a UK-based government agency, reported that 32.5 million dental treatments were provided in 2022-23, marking a 23.2% increase compared to the previous year. As a result, the growing prevalence of oral health issues is fueling the expansion of the salivary gland infections market.

Companies in the salivary gland infections market are focusing on technological advancements, particularly in minimally invasive procedures, to improve treatment outcomes, accelerate patient recovery, and enhance healthcare efficiency. Minimally invasive techniques involve smaller incisions and specialized tools, reducing tissue damage and promoting faster healing. For instance, in March 2024, Amrita Hospital, an India-based healthcare institution, launched the Amrita Centre for Minimally Invasive Salivary Gland Surgery. This initiative introduces sialendoscopy, a groundbreaking technique for treating salivary disorders while minimizing the need for surgery and preserving glandular function. The launch featured a two-day workshop showcasing expert demonstrations of the procedure.

In November 2022, Navamedic ASA, a Norway-based pharmaceutical company, acquired the rights and marketing authorizations for clindamycin ready-to-administer bags from ACS Dobfar for an undisclosed sum. This acquisition strengthens Navamedic’s product portfolio, increases revenue potential, and reinforces its market presence in the Nordic region. ACS Dobfar, an Italy-based pharmaceutical company, specializes in the development of clindamycin, which is commonly used to treat salivary gland infections.

Major players in the salivary gland infection market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences, Inc., Amgen Inc., FUJIFILM Holdings Corporation, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Astellas Pharma Inc., Sandoz International GmbH, Vertex Pharmaceuticals Incorporated, Incyte Corporation., Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Vanda Pharmaceuticals Inc, Mylan N.V., and Zydus Cadila Healthcare Ltd.

North America was the largest region in the salivary gland infection market in 2024. The regions covered in salivary gland infections report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the salivary gland infections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Salivary gland infections are bacterial or viral infections affecting the salivary glands, causing symptoms such as swelling, pain, and dry mouth. These infections commonly occur in the major salivary glands, including the parotid, submandibular, and sublingual glands, and may result from blockage, dehydration, or infections such as mumps.

The primary diagnostic methods for salivary gland infections include plain radiography, sialography, computed tomography (CT), magnetic resonance imaging (MRI), radionuclide scintigraphy, high-resolution ultrasonography, and other techniques. Plain radiography is an imaging method that uses X-rays to visualize internal body structures, including the salivary glands, and is useful for detecting stones or calcifications. Treatment options include medications, surgery, aspiration, home care, and other therapies. These services are provided across hospitals and clinics, medical research centers, academic institutions, and other healthcare settings.

The salivary gland infections market research report is one of a series of new reports that provides salivary gland infection market statistics, including the salivary gland infection industry's global market size, regional shares, competitors with a salivary gland infection market share, detailed salivary gland infection market segments, market trends and opportunities, and any further data you may need to thrive in the salivary gland infection industry. This salivary gland infection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The salivary gland infections market consists of revenues earned by entities by providing services such as ultrasound, rehabilitation therapy, and glandular duct dilation procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The salivary gland infections market includes sales of antibiotics, antiviral drugs, anti-inflammatory medications, and biocompatible stents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.